{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Non-complete Response/ Non-progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"title":"Not evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"}],"units":"Participants"}],"description":"Confirmed BOR was determined according to RECIST 1.1and as adjudicated by an Independent Endpoint Review Committee(IERC) and defined as best response of any of complete response (CR), partial response(PR), stable disease(SD) and progressive disease(PD) recorded from date of randomization until disease progression/recurrence(taking smallest measurement recorded since start of treatment as reference). CR:Disappearance of all evidence of target/non-target lesions. PR:At least 30%reduction from baseline in sum of longest diameter(SLD) of all lesions. SD:Neither sufficient increase to qualify for PD nor sufficient shrinkage to qualify for PR. PD:at least a20% increase in SLD, taking as reference smallest SLD recorded from baseline/appearance of 1or more new lesions and unequivocal progression of non-target lesions. CR or PR must be confirmed by a subsequent tumor assessment preferably at next scheduled 6-weekly assessment, but no sooner than 5 weeks after initial documentation of CR or PR.","groups":[{"description":"Participants with metastatic Merkel cell carcinoma (MCC) after failing first-line chemotherapy received Avelumab at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.","id":"OG000","title":"Part A: Avelumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent-to-Treat analysis set included all participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to 113 weeks","title":"Part A: Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1","type":"PRIMARY","unitOfMeasure":"Participants"}